anti-mouse sirt2 (ZenBio)
Structured Review

Anti Mouse Sirt2, supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse sirt2/product/ZenBio
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation"
Article Title: E3 Ubiquitin Ligase HRD1 Promotes Lung Tumorigenesis by Promoting Sirtuin 2 Ubiquitination and Degradation
Journal: Molecular and Cellular Biology
doi: 10.1128/MCB.00257-19
Figure Legend Snippet: HRD1 deficiency upregulated the expression of SIRT2 as determined using mass spectrometry analysis. (A) The network view of the predicted E3 ligase of SIRT2 by UbiBrowser. The query substrate is located in the center of the canvas. The predicted E3 ligases surround the substrate. The node colors and characters reflect the E3 type. The edge width, the node size, and the edge shade are corrected with the confidence score. Node size, edge color depth, and edge width are proportional to the confidence score. H, HECT; U, UBOX; F, F-box; R, RING; C, CDC20; D, DWD; S, SOCS. (B and C) Proteomic analysis of genes differentially expressed between control and HRD1 knockout A549 cells. Diagrams depict 87 HRD1-repressed genes and 126 HRD1-activated genes. (D) Representative showing of HRD1-activated and -repressed genes by KEGG analysis.
Techniques Used: Expressing, Mass Spectrometry, Knock-Out
Figure Legend Snippet: SIRT2 interacts with HRD1. (A) The Myc-SIRT2 expression plasmid was cotransfected with or without HRD1-Flag into HEK293T cells. The SIRT2 protein was immunoprecipitated (IP) with the anti-Flag antibody, and the expression of SIRT2 and HRD1 in the whole-cell lysate (WCL) was confirmed by immunoblotting (IB) with antibodies against Myc and Flag. (B) The HRD1-Myc expression plasmid was cotransfected with or without Flag-SIRT2 into HEK293T cells. The HRD1 protein was immunoprecipitated with anti-Flag antibody, and the expression of SIRT2 and HRD1 in the WCL was confirmed by IB with antibodies against Myc and Flag. (C) HEK293T cells were cotransfected with the HRD1-Myc expression plasmid and Flag-SIRT1 to Flag-SIRT7. The HRD1 protein was immunoprecipitated with the anti-Flag antibody. The expression of HRD1 and SIRTs in the WCL was confirmed by IB with antibodies against Myc and Flag. (D) The endogenous interaction of HRD1 and SIRT2 was evaluated in A549 cells. A normal mouse IgG (mIgG) was used as a control. (E) Schematic representation of SIRT2 and its mutants, indicating that SIRT2 contains a CORE domain. (F) Schematic representation of HRD1 and its mutants, showing that HRD1 protein contains an N-terminal signal peptide, transmembrane domain, zinc finger domain, and C-terminal proline-rich domain. (G) The interactions of SIRT2 and its mutants with HRD1 protein were evaluated. HRD1-Flag plasmids were cotransfected with SIRT2 or each of its mutants, and their interactions were analyzed as for panel A. (H) The interactions of SIRT2 with HRD1 and its mutants were evaluated. Flag-SIRT2 plasmids were cotransfected with HRD1 or each of its mutants into HEK293T cells, and their interactions were analyzed as for panel A. For panels A to D, F, and H, numbers on the left are molecular masses, in kilodaltons. (I) Colocalization of HRD1 and PDI, SIRT2 and PDI1, and HRD1 and SIRT2 in HeLa cells. The cellular localization of HRD1, SIRT2, and PDI was examined by immunofluorescence staining with corresponding antibodies. 4,6-Diamidino-2-phenylindole (DAPI) was used to stain the DNA.
Techniques Used: Expressing, Plasmid Preparation, Immunoprecipitation, Western Blot, Immunofluorescence, Staining
Figure Legend Snippet: HRD1 promotes SIRT2 ubiquitination. (A) HA-ubiquitin, Flag-SIRT2, and HRD1-Myc plasmids were cotransfected into HEK293T cells. SIRT2 ubiquitination was detected by immunoprecipitation of SIRT2 with the anti-Flag antibody and Western blotting with anti-HA antibody. The protein expression levels of HA-ubiquitin, SIRT2, and HRD1 in the whole-cell lysates were confirmed. (B) HA-ubiquitin and Flag-SIRT2 expression plasmids were cotransfected with HRD1-Myc or Myc-UHRF1 into HEK293T cells. SIRT2 ubiquitination was analyzed as for panel A. (C) Schematic representation of HRD1 and its point mutants. The conserved cysteine (C) residues in the RING domain were replaced with alanine (A). (D) HA-ubiquitin and Flag-SIRT2 expression plasmids were cotransfected into HEK293T cells with HRD1-Myc or with HRD1/CA mutants. The effects of HRD1 and its mutants on SIRT2 ubiquitination were analyzed as for panel A. (E) The interactions of SIRT2 with wild-type (wt) HRD1 or its mutants were analyzed as indicated for panel C. (F) HA-ubiquitin expression plasmids were transfected into the control and the stable knockdown HRD1 A549 cancer cells. SIRT2 ubiquitination was detected via immunoprecipitation of SIRT2 with anti-SIRT2 antibody and Western blotting with anti-UB antibody. The protein expression levels of SIRT2 and HRD1 in the whole-cell lysates were confirmed.
Techniques Used: Immunoprecipitation, Western Blot, Expressing, Transfection
Figure Legend Snippet: HRD1 negatively regulates SIRT2 protein stability. (A and B) HRD1 expression plasmids or empty vectors were cotransfected with Flag-SIRT2 into HEK293T cells. The transfected cells were treated with cycloheximide (CHX) for different times. The protein levels in the treated cells were determined by Western blotting using anti-Flag (A, top) and anti-Myc (A, middle) antibodies (Abs). β-Actin was used as a loading control (A, bottom). The band intensities of SIRT2 proteins were quantified, and their relative levels are shown in panel B. (C and D) HRD1 expression plasmids or empty vectors were transfected into HEK293T cells. The transfected cells were treated with CHX for different times. The protein levels in the treated cells were determined through Western blotting using anti-SIRT2 (C, top) and anti-Myc (C, middle) Abs. β-Actin was used as a loading control (C, bottom). The band intensities of SIRT2 proteins were quantified, and their relative levels are shown in panel D. (E) A fraction of cells from panel A was prepared in parallel for total RNA extraction. The mRNA levels of both SIRT2 and HRD1 were determined by real-time PCR. Their relative levels are indicated. The error bar represents the SEMs from triplicate experiments. **, P < 0.05, two-tailed Student’s t test. (F and G) HRD1 or HRD1/CA mutant plasmids were transfected into HEK293T cells. SIRT2 protein stabilities in the transiently transfected HEK293T cells were examined as described for panels A and B. (H and I) A549 cells stably expressing control shRNA or HRD1-specific shRNA (shHRD1-1 and shHRD1-2) were treated with CHX for the indicated time. SIRT2 protein stabilities were analyzed as described for panel A (H, top). The expression levels of HRD1 (H, middle) were confirmed through Western blotting using β-actin as a loading control (H, bottom). The band intensities of SIRT2 proteins were quantified, and their relative levels are shown in panel I. (J) A549 cells stably expressing control or HRD1 knockdown plasmids were treated with the proteasome inhibitor MG132. The protein levels of SIRT2 (top) and HRD1 (middle) were determined by Western blotting with GAPDH as a loading control (bottom).
Techniques Used: Expressing, Transfection, Western Blot, RNA Extraction, Real-time Polymerase Chain Reaction, Two Tailed Test, Mutagenesis, Stable Transfection, shRNA
Figure Legend Snippet: HRD1 knockdown suppresses lung cancer cell proliferation and tumorigenesis. (A and B) The cell proliferation of A549 cancer cells stably expressing the indicated plasmids or combination of plasmids was determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. The error bars represent the SEMs from triplicate experiments. HRD1 2CA mutant C291, 294A was used. The protein levels of SIRT2, HRD1, or both were determined by Western blotting using β-actin as a loading control in A549 cells stably expressing control vector or indicated overexpression or knockdown plasmids. (C to F) A clonogenic assay was performed to measure the colony formation capacity of A549 cancer cells stably expressing the indicated plasmids (C) or stably expressing the indicated knockdown plasmids (E). The quantitation of colony number is shown in panels D and F. Error bars represent the SD from triplicate experiments. *, P < 0.05. (G to I) A549 cells stably expressing control, HRD1 knockdown, and HRD1 plasmids were injected subcutaneously into nude mice. Six weeks after injection, tumors were isolated and photographed (G). The tumor sizes were measured and are depicted as tumor weight (H) and tumor volume (I).
Techniques Used: Stable Transfection, Expressing, MTS Assay, Mutagenesis, Western Blot, Plasmid Preparation, Over Expression, Clonogenic Assay, Quantitation Assay, Injection, Isolation
Figure Legend Snippet: HRD1 knockdown inhibits cell migration and invasion in lung cancer cells. (A to D) Wound-healing assays were performed to measure the migration of A549 cells stably expressing the indicated knockdown or overexpression plasmids or a combination of plasmids. Cells were monitored within 24 h to evaluate the rate of migration into the scratched area. The wound edges are indicated by black lines in panels A and C. The relative distances of migration are shown in panels B and D. The results represent the means ± SEMs from triplicate experiments. *, P < 0.05; **, P < 0.01. (E to J) The effects of stable knockdown (E to H) or overexpression (I and J) of HRD1 or SIRT2 on cell invasion were measured in A549 cells (E, F, I, and J) or H446 cells (G and H) by Matrigel Transwell assays. The quantitative results are shown. The results represent the means and SD from triplicate experiments. *, P < 0.05; **, P < 0.01. (K) The protein levels of HRD1, SIRT2, ac-H4K16 were determined by Western blotting using β-actin as a loading control in A549 cells stably expressing control or HRD1 knockdown plasmids.
Techniques Used: Migration, Stable Transfection, Expressing, Over Expression, Western Blot
Figure Legend Snippet: HRD1 and SIRT2 expression in lung cancer. (A) The protein levels of HRD1 and SIRT2 were measured in lung cancer tissue specimens (T; n = 8) and matched with adjacent normal tissues (N; n = 8) through Western blotting. (B) The relative HRD1 and SIRT2 protein levels in normal and cancer tissues were quantified. (C) Representative images showing the immunohistochemical staining of HRD1 and SIRT2 in normal and lung cancer tissues. (D) Analysis of the GEPIA data indicates a significant positive correlation of SIRT2 expression and a negative correlation of HRD1 expression between their expression and the overall survival of lung adenocarcinoma patients. GEPIA uses the log rank test, also known as the Mantel-Cox test, for the hypothesis test. The Cox proportional hazard ratio and the 95% confidence interval information are also included in the survival plot. (E) Schematic model of SIRT2 regulation by HRD1. Upregulation of HRD1 in lung cancer patients leads to downregulation of SIRT2, thus resulting in enhanced cell proliferation and lung tumorigenesis.
Techniques Used: Expressing, Western Blot, Immunohistochemical staining, Staining

